Pipeline Information
Learn more about our R&D pipeline and ongoing trials below
Development Programs – Solid Tumor
Drug
Indication
Phase 1
Phase 2
Phase 3
BGB-3245 (BRAF inhibitor)
Advanced solid tumors with B-RAF mutations
Lifirafenib (RAF inhibitor) + PD-0325901 (MEK inhibitor)
Advanced solid tumors
Pamiparib (PARP 1/2 inhibitor)
2L/3L maintenance platinum-sensitive OC
1L maintenance platinum-sensitive GC
≥2L CTC HRD+ mCRPC
BRCA+ and HER2– BC
Advanced OC and TNBC
Pamiparib + Radiotherapy and/or Temozolomide
1L or R/R GBM
Pamiparib + Temozolomide
Advanced solid tumors
Tislelizumab (anti-PD-1)
2L advanced ESCC
1L HCC
2L/3L NSCLC
Advanced UBC
Previously treated unresectable HCC
Previously treated advanced MSI-high or dMMR solid tumors
Advanced solid tumors
Advanced solid tumors
Tislelizumab + BGB-A333 (anti-PD-L1)
Advanced solid tumors
Tislelizumab + BGB-A425 (anti-TIM-3)
Advanced solid tumors
Tislelizumab + BGB-A445 (anti-OX40)
Advanced solid tumors
Tislelizumab + BGB-A1217 (anti-TIGIT)
Advanced solid tumors
Tislelizumab + BGB-10188 (PI3Kδ inhibitor)
Advanced solid tumors
Tislelizumab + Chemoradiotherapy
Localized ESCC
Tislelizumab + Chemotherapy
1L advanced ESCC
1L GC/GEJC
Resectable stage II or IIIA NSCLC
1L advanced nasopharyngeal cancer
1L squamous NSCLC
1L non-squamous NSCLC
1L advanced UBC
1L ES-SCLC
1L GC/GEJC/ESCC
1L SCLC and NSCLC
Tislelizumab + DKN-01 (anti-DKK1) + Chemotherapy
1L/2L GC/GEJC
Tislelizumab + Lenvatinib
1L HCC
Tislelizumab + Pamiparib
Advanced solid tumors
Tislelizumab + Sitravatinib (multikinase inhibitor)
Advanced GC/GEJC/HCC
Advanced solid tumors
Zanidatamab (anti-HER2 bispecific antibody)
2L+ HER2+ BTC
Zanidatamab + Chemotherapy +/- Tislelizumab
1L HER2+ BC and 1L HER2+ GC/GEJC
Australia
Australia, China
China
China, S. Korea
China, Taiwan, Thailand
S. Korea, Taiwan
US, Australia
United States
Worldwide
BC, breast cancer BRCA+, breast cancer susceptibility gene-positive; dMMR, deficient mismatch repair; ESCC, esophageal squamous cell carcinoma; ES-SCLC; extensive-stage small cell lung cancer; GC, gastric cancer; GEJC, gastroesophageal junction carcinoma; HCC, hepatocelluar carcinoma; HER2-, human epidermal growth factor receptor-2–negative; HER2+, human epidermal growth factor receptor-2–positive; MSI, microsatellite instability; NSCLC, non-small cell lung cancer; OC, ovarian cancer; R/R, recurrent/refractory; SCLC, small lung cell cancer; TNBC, triple-negative breast cancer; UBC, urothelial bladder cancer.
Development Programs – Hematology
Drug
Indication
Phase 1
Phase 2
Phase 3
Tislelizumab (anti-PD-1)
R/R mature T- and NK-cell neoplasms
R/R cHL
R/R cHL
BGB-10188 (PI3Kδ inhibitor) +/- Zanubrutinib (BTK inhibitor)
B-cell lymphoid malignancies
BGB-11417 (Bcl-2 inhibitor) monotherapy
Mature B-cell malignancies
ME-401 (PI3Kδ inhibitor) +/- Zanubrutinib or Rituximab*
CLL/SLL, and B-cell NHL
Zanubrutinib
R/R CLL/SLL
1L and R/R WM
R/R CLL/SLL
R/R MCL
R/R non-GCB type DLBCL
R/R WM
R/R MZL
B-cell lymphoid malignancies
Previously treated B-cell lymphoid malignancies
B-cell lymphoid malignancies
B-cell lymphoid malignancies
Zanubrutinib + Obinutuzumab
R/R FL
B-cell lymphoid malignancies
Zanubrutinib + Rituximab
1L MCL
R/R DLBCL (non-GCB) and R/R indolent lymphoma (FL, MZL)
Zanubrutinib + Tislelizumab
B-cell lymphoid malignancies
Zanubrutinib +/- Venetoclax†
1L CLL/SLL
Australia
Australia, China
China
Japan
United States
United States, Switzerland
Worldwide
* In collaboration with MEI Pharma
† This combination is being studied in the third cohort of NCT03336333
BC, breast cancer; B-cell NHL, B-cell non-Hodgkins lymphoma; cHL, classical Hodgkin lymphoma; CLL, chronic lymphotic leukemia; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; GCB, germinal center B cell-like; MCL, mantle cell lymphoma; MZL, marginal zone lymphoma; NK, natural killer; R/R, recurrent/refractory; SLL, small lymphocytic lymphoma; WM, Waldenstrӧm macroglobulinemia.
Interactive Clinical Pipeline
Videos
Anti-PD-1 Mechanism of Action
BTKI Mechanism of Action
